Phase 4 Completed N=104 Treatment

An Open Label, Multi Centre Phase IV Study of Adefovir Dipivoxil in Korean Patients With Chronic Hepatitis B (CHB)

Hepatitis B, Chronic

Source: ClinicalTrials.gov NCT01205165 ↗

Enrolled (actual)

104

Serious AEs

1.9%

Results posted

Mar 2018

Primary outcomePrimary: Mean Log 10 Reduction in Serum Hepatitis B Virus (HBV), Deoxyribonucleic Acid (DNA) Level From Baseline to Week 12 — -3.39 Log10 (copies/mL) — p=0.00000

◆ Published Evidence

No publication linked

No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.

Summary

Objective(s) The primary study objective is to assess the antiviral effect of 12 weeks of adefovir dipivoxil treatment in Korean patients with chronic hepatitis B and compensated liver disease. The secondary study objectives are to assess the antiviral effect, clinical benefit and safety of 52 weeks of adefovir dipivoxil treatment. Endpoint(s) The primary efficacy endpoint is "Mean log10 reduction in serum HBV DNA level from baseline to Week 12". The secondary efficacy endpoints include (a) the proportion of patients achieving serum ALT normalization at Week 52, (b) other assessments of antiviral effects (the proportion of patients achieving HBV DNA no less than 300 copies per mL at Week 52), (c)HBeAg loss, HBeAg seroconversion, HBsAg loss and HBsAg seroconversion, (d)the proportion of patients achieving serum ALT normalization at Week 12. Study Design This is an open label, multi centre phase IV study for Korean patients with chronic hepatitis B and compensated liver disease, assessing the antiviral effect of 12 weeks treatment of Adefovir dipivoxil as a primary objective and antiviral effect, clinical benefit and safety of 52 weeks treatment as secondary objectives. Patients will be screened for eligibility criteria and the baseline visit for the treatment initiation should occur no more than 4 weeks after screening. Total treatment period will be 52 weeks and patients will return to the clinic for assessments as scheduled during treatment period. After the 52 week study period, it is likely that the patient will benefit from continued treatment with commercial adefovir. If in the investigator's clinical judgement this is the case, the investigator should ensure that a routine prescription is available in a timely manner, and that no unnecessary interruption in treatment occurs. Study Population A minimum of 100 male or female Korean patients more than 18 years of age with HBeAg positive chronic hepatitis B and compensated liver disease who meet the eligibility criteria will be enrolled. Study Assessments and Procedures Potential patients will be screened prior to study entry and eligible patients who have given their consent will have further baseline assessments. Following the screening, the first doses of study medications will be given at baseline and patients will return to the clinic for assessment as scheduled during treatment period. Patients who discontinue treatment prematurely will be followed up every 4 weeks for 12 weeks following the withdrawal visit. The following key assessment and or measurement will be made at one or more visits during the study. (See section 14.1 Appendix 1. Time and event schedule): * Pregnancy test (females of child-bearing potential only) * Haematology and serum chemistry profile including prothrombin time(PT) and AFP * HBV DNA (Roche COBAS AMPLICOR HBV MONITOR Test, LLOD 300 copies per ml) * Hepatitis B markers: HBeAg(Anti HBe will be tested if HBeAg is negative), HBsAg(Anti HBs will be tested if HBsAg is negative) Investigational Product(s) Adefovir dipivoxil 10mg tablets will be supplied by GlaxoSmithKline and presented as a white to off white, round tablets, packaged in the bottle containing 30 tablets

Outcome Measures

Outcome	Result	p-value
PRIMARY Mean Log 10 Reduction in Serum Hepatitis B Virus (HBV), Deoxyribonucleic Acid (DNA) Level From Baseline to Week 12	-3.39	0.00000 sig
SECONDARY Number of Participants Achieving Alanine Aminotransferase (ALT) Normalization at Week 52	83	—
SECONDARY Number of Participants Achieving Virological Response at Week 52	34	—
SECONDARY HBV DNA Levels at Each Collection Timepoint Through Week 52	5.59; 4.96; 4.56; 3.97; 3.92; 3.78	—
SECONDARY Number of Participants With Hepatitis B e Viral Protein (HBeAg) Loss, HBeAg Seroconversion, Hepatitis B Virus Surface Antigen (HBsAg) Loss and HBsAg Seroconversion at Week 52	19; 10; 0; 0	—
SECONDARY Number of Participants Achieving ALT Normalization at Week 12	50	—
SECONDARY Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAEs)	2; 43; 6	—
SECONDARY Number of Participants With Shift From Baseline Hematology Parameters at Week 12 and Week 52	0; 0; 0; 3; 1; 3	—
SECONDARY Number of Participants With Shift From Baseline Clinical Chemistry Parameters at Week 12 and Week 52	0; 0; 0; 2; 0; 1	—
SECONDARY Mean Log 10 Reduction in Serum HBV DNA Level From Baseline to Week 52	-4.32	—

Eligibility Criteria

Inclusion Criteria

A subject will be eligible for inclusion in this study only if all of the following criteria apply:

Age more than 18 years
HBV Serology Presence of HBsAg for at least 6 months Presence of HBeAg at the time of screening Positive HBV DNA plasma assay with screening value at the time of screening
Evidence of at least one elevated serum alanine amonotransferase (ALT) levels greater than 2 times (inclusive) the upper limit of the normal range (ULN) in the previous 6 months.

serum ALT levels greater than 2 times (inclusive) the ULN at screening visit. 5. Availability and willingness of subject to provide written informed consent.

Exclusion Criteria

A subject will not be eligible for inclusion in this study if any of the following criteria apply:

Use of immunosuppressive therapy requiring use of more than 5mg of prednisone(or equivalent) per day, immunomodulatory therapy (including interferon or thymosin ) or systemic cytotoxic agents within previous 6 months or during the study
Previous or current lamivudine or adefovir dipivoxil therapy or antiviral therapy with agents demonstrating potential anti-HBV activity
Clinical signs of decompensated liver disease at screening according to the protocol
Serum creatinine over 1.5mg per dL
Alanine aminotransferase (ALT) over 10 times ULN at screening or history of acute exacerbation leading to transient decompensation
Serum Amylase and/or lipase over 2 times ULN
Inadequate haematological function
Anti-HBe or Anti-HBs positive subjects
Hepatocellular carcinoma as evidenced by the protocol
Documented evidence of active liver disease
Any serious or active medical or psychiatric illnesses other than hepatitis B which, in the opinion of the investigator, would interfere with patient treatment, assessment or compliance with the protocol. This would include any uncontrolled clinically significant renal, cardiac, pulmonary, vascular, neurogenic, digestive, metabolic (diabetes, thyroid disorders, adrenal disease), immunodeficiency disorders or cancer.
Active alcohol or drug abuse or history of alcohol or drug abuse considered by the investigator to be sufficient to hinder compliance with treatment, participation in the study or interpretation of results.
Planned for liver transplantation or previous liver transplantation
Receipt of any investigational drug within within 3 months prior to screening.
Therapy with nephrotoxic drugs or competitors of renal excretion within 2 months prior to study screening or the expectation that patient will receive any of these during the course of the study.
History of hypersensitivity to nucleoside and/or nucleotide analogues.
Inability to comply with study requirements as determined by the study investigator.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01205165). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.